Triiodothyronine (T3) Augmentation for Treatment-Resistant Depression
T3 augmentation is a reasonable and evidence-supported option for treatment-resistant depression after failure of at least two adequate antidepressant trials, with a typical dose of 25-50 mcg/day added to ongoing antidepressant therapy.
Evidence Base and Efficacy
The research supporting T3 augmentation shows modest but clinically meaningful benefits in treatment-resistant depression (TRD). A meta-analysis of tricyclic antidepressant augmentation demonstrated that patients treated with T3 were twice as likely to respond compared to controls (relative response 2.09,95% CI 1.31-3.32), corresponding to a 23.2% absolute improvement in response rates 1. However, the quality of evidence was uneven, and when limited to only randomized double-blind studies, the pooled effects were not statistically significant.
For SSRI augmentation specifically, the evidence is more limited but still supportive. In the landmark STAR*D trial comparing lithium versus T3 augmentation after two failed medication trials, remission rates were 24.7% with T3 versus 15.9% with lithium (though not statistically significant) 2. Critically, T3 had significantly fewer side effects (p=0.045) and lower discontinuation rates due to adverse effects (9.6% vs 23.2%, p=0.027) 2.
An open-label study of SSRI-resistant depression showed a 42% response rate (≥50% improvement on HAMD scores) with T3 augmentation, with three patients achieving full remission 3. A systematic review concluded that while evidence for T3 with SSRIs is less robust than with tricyclics, available data support its use in augmentation strategies 4.
Practical Implementation
Dosing Protocol
- Starting dose: 25 mcg daily
- Target dose: Increase to 50 mcg daily within one week if tolerated 3
- Duration of trial: Minimum 3 weeks to assess response 3
- Continue the patient's existing antidepressant at the same dose
Patient Selection Criteria
Based on consensus guidelines, appropriate candidates have 5:
- Failed at least two adequate antidepressant trials (different mechanisms of action)
- Each trial at minimum licensed dose for at least 4 weeks
- Current MADRS score or HAMD-17 score indicating inadequate response
- Normal thyroid function (TSH within normal range) 3
- Non-psychotic major depressive disorder
Safety Monitoring Requirements
Baseline assessment:
- TSH, free T4, free T3
- Cardiovascular evaluation (ECG if age >50 or cardiac risk factors)
- Bone density consideration in postmenopausal women or those with risk factors
Follow-up monitoring:
- Thyroid function tests at 4-6 weeks, then every 3 months 6
- Monitor for cardiac symptoms (palpitations, chest pain, tachycardia)
- Assess for signs of hyperthyroidism (tremor, anxiety, weight loss, heat intolerance)
- Bone density monitoring annually in at-risk populations 6
Advantages Over Alternative Augmentation Strategies
T3 has distinct practical advantages:
- Better tolerability than lithium with lower side effect burden 2
- No need for blood level monitoring (unlike lithium)
- Rapid onset of potential benefit (within 2-3 weeks)
- Inexpensive and widely available 3
- Ease of use compared to lithium's narrow therapeutic window 2
Important Caveats and Contraindications
Relative contraindications:
- Active cardiovascular disease (use lower starting dose of 10-20 mcg if necessary) 7
- Uncontrolled hyperthyroidism
- Acute myocardial infarction
- Uncorrected adrenal insufficiency
Common pitfalls to avoid:
- Discontinuing trial before 3 weeks (insufficient time to assess response)
- Using T3 as first-line treatment rather than after adequate antidepressant trials
- Failing to verify euthyroid status before initiation
- Inadequate cardiovascular screening in older adults
Context Within Treatment Algorithm
According to current TRD definitions, patients should have failed two adequate trials of licensed antidepressants with different mechanisms of action before considering augmentation strategies 5. The 2022 Delphi consensus strongly recommends (93% agreement) that patients who have failed augmentation strategies should not be excluded from further treatment trials 5.
While newer options like ketamine and esketamine show promise for TRD 8, they are reserved for patients with multiple treatment failures and require specialized administration. T3 augmentation remains a practical, office-based option that can be implemented before escalating to more intensive interventions like brain stimulation therapies.
The evidence suggests T3 augmentation works across different antidepressant classes, though most robust data exists for tricyclics and SSRIs 1, 4. Response rates of 24-42% represent meaningful clinical benefit for a population with limited options 2, 3.